|
Jun 24
|
Ultimovacs ASA announces revised terms of the employee share option program
|
|
Apr 30
|
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
|
|
Jan 2
|
Ultimovacs ASA: Mandatory notification of trade by primary insider
|
|
Nov 28
|
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
|
|
Oct 23
|
Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 Cancer Vaccine
|
|
Oct 17
|
Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Malignant Mesothelioma
|